Abstract

HIV infection and initiation of antiretroviral therapy (ART) have been consistently associated with decreased bone mineral density (BMD), with growing evidence linking HIV to an increased risk of fracture. This is especially concerning with the expanding number of older persons living with HIV. Interestingly, recent data suggest that HIV-infected children and youth fail to achieve peak BMD, possibly increasing their lifetime risk of fracture. Elucidating the causes of the bone changes in HIV-positive persons is challenging because of the multifactorial nature of bone disease in HIV, including contribution of the virus, immunosuppression, ART toxicity, and traditional osteoporosis risk factors, such as age, lower weight, tobacco, and alcohol use. Thus, practitioners must recognize the risk of low BMD and fractures and appropriately screen patients for osteoporosis if risk factors exist. If fractures do occur or elevated fracture risk is detected through screening, treatment with bisphosphonate medications appears safe and effective in the HIV + population.

Keywords

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Amy H. Warriner has received research funding from NIH, AHRQ, Astra Zeneca, Bristol-Myers Squibb/Amylin; holds a role on the advisory board for Janssen; and has received payment from ISCD and AACE for lectures. Michael Mugavero reports grants from Bristol Meyers Squibb, grants from Definicare, grants from Pfizer for outside the submitted work; and has received consulting fees from Bristol Meyers Squibb, Merck, and Gilead. E. Turner Overton reports other from Gilead Sciences for outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

Maalouf NM, Zhang S, Drechsler H, et al. Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. J Bone Miner Res. 2013;28:2577–83. In this large study of over 56,000 veterans included in a case registry over 25 years, fractures were found to be more prevalent among HIV/HCV co-infected than HIV-infected patients and the degree of liver disease (determined through and indirect assessment of liver fibrosis) partially explained the difference between these groups.PubMedCrossRefGoogle Scholar

Assoumou L, Katlama C, Viard JP, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27:2425–30. Compared with other ART regimen, patients treated with tenofovir were found to have significant loss of BMD over a 2-year period.PubMedCrossRefGoogle Scholar

Yin MT, Lund E, Shah J, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. AIDS. 2014;28:345–53. In this cross-sectional study of African-American and Hispanic men who were infected with HIV during childhood or adolescence, peak bone mass was lower than in HIV uninfected men and bone microachitecture was altered.PubMedCentralPubMedCrossRefGoogle Scholar

58.•

DiMeglio LA, Wang J, Siberry GK, et al. Bone mineral density in children and adolescents with perinatal HIV infection. AIDS. 2013;27:211–20. In this cross-sectional study of children in the U.S. and Puerto Rico, lower BMD was seen in the HIV + than expected, which was partially explained by delayed growth.PubMedCrossRefGoogle Scholar